Naperol Investments Ltd
Incorporated in 1954, National Peroxide Ltd is engaged in Investment and Leasing business[1]
- Market Cap ₹ 566 Cr.
- Current Price ₹ 985
- High / Low ₹ 2,041 / 772
- Stock P/E 53.6
- Book Value ₹ 2,041
- Dividend Yield 0.92 %
- ROCE 1.06 %
- ROE 0.95 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.48 times its book value
- Market value of investments Rs.1,062 Cr. is more than the Market Cap Rs.568 Cr.
- Debtor days have improved from 135 to 76.5 days.
Cons
- The company has delivered a poor sales growth of -37.7% over past five years.
- Company has a low return on equity of 0.40% over last 3 years.
- Working capital days have increased from -75.2 days to 162 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Finance Industry: Finance & Investments
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
234 | 196 | 233 | 233 | 306 | 402 | 208 | 226 | 232 | 2 | 2 | 20 | |
173 | 174 | 197 | 163 | 161 | 175 | 166 | 170 | 209 | 2 | 3 | 8 | |
Operating Profit | 61 | 22 | 36 | 70 | 145 | 226 | 42 | 56 | 23 | -0 | -1 | 11 |
OPM % | 26% | 11% | 15% | 30% | 47% | 56% | 20% | 25% | 10% | -13% | -32% | 57% |
7 | 6 | 7 | -2 | 11 | 19 | 1 | -15 | 10 | 376 | 0 | 1 | |
Interest | 0 | 5 | 5 | 2 | 1 | 1 | 3 | 13 | 9 | 0 | 0 | 0 |
Depreciation | 10 | 7 | 9 | 9 | 9 | 9 | 11 | 18 | 17 | 0 | 0 | 0 |
Profit before tax | 58 | 16 | 29 | 57 | 146 | 235 | 29 | 12 | 7 | 376 | -1 | 12 |
Tax % | 34% | 62% | 37% | 34% | 35% | 35% | 40% | -76% | 32% | 0% | -41% | 10% |
39 | 6 | 18 | 38 | 95 | 153 | 17 | 21 | 5 | 375 | -0 | 11 | |
EPS in Rs | 67.75 | 10.93 | 31.53 | 66.46 | 166.88 | 268.47 | 30.47 | 36.51 | 8.93 | 658.33 | -0.65 | 18.51 |
Dividend Payout % | 22% | 46% | 32% | 52% | 39% | 24% | 41% | 35% | 56% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -21% |
5 Years: | -38% |
3 Years: | -56% |
TTM: | 919% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | -9% |
3 Years: | 300% |
TTM: | 2951% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | -6% |
3 Years: | -4% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 1% |
3 Years: | 0% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 201 | 203 | 214 | 368 | 503 | 609 | 481 | 583 | 532 | 552 | 1,049 | 1,158 |
4 | 73 | 30 | 11 | 0 | 80 | 161 | 125 | 94 | 0 | 0 | 0 | |
59 | 62 | 60 | 55 | 76 | 88 | 94 | 71 | 63 | 1 | 23 | 42 | |
Total Liabilities | 270 | 344 | 310 | 440 | 585 | 783 | 742 | 785 | 694 | 559 | 1,078 | 1,205 |
117 | 187 | 180 | 178 | 170 | 166 | 372 | 342 | 338 | 0 | 0 | 0 | |
CWIP | 41 | 4 | 3 | 2 | 6 | 75 | 0 | 3 | 4 | 0 | 0 | 0 |
Investments | 10 | 10 | 7 | 170 | 253 | 192 | 177 | 268 | 282 | 547 | 1,065 | 1,190 |
102 | 143 | 120 | 90 | 156 | 350 | 193 | 172 | 71 | 12 | 13 | 16 | |
Total Assets | 270 | 344 | 310 | 440 | 585 | 783 | 742 | 785 | 694 | 559 | 1,078 | 1,205 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
28 | 21 | 22 | 59 | 94 | 148 | 16 | 61 | 9 | 1 | 1 | -3 | |
-21 | -75 | 30 | -31 | -56 | -175 | -38 | -7 | 34 | 1 | 0 | 11 | |
-7 | 54 | -51 | -28 | -35 | 35 | 14 | -49 | -49 | -3 | -1 | -6 | |
Net Cash Flow | 0 | 0 | -0 | -0 | 3 | 8 | -9 | 4 | -6 | -0 | 1 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 51 | 69 | 51 | 52 | 64 | 28 | 57 | 38 | 30 | 193 | 0 | 76 |
Inventory Days | 134 | 76 | 65 | 66 | 65 | 134 | 98 | 87 | 87 | 0 | ||
Days Payable | 126 | 120 | 83 | 115 | 90 | 101 | 75 | 102 | 41 | |||
Cash Conversion Cycle | 59 | 25 | 33 | 4 | 39 | 61 | 80 | 23 | 76 | 193 | 0 | 76 |
Working Capital Days | 72 | 150 | 102 | 64 | 115 | 238 | 230 | 197 | 42 | -85 | -302 | 162 |
ROCE % | 30% | 9% | 13% | 21% | 33% | 39% | 5% | 6% | 1% | -0% | -0% | 1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 May - In compliance with Regulation 30, 47 and other applicable provisions of Listing Regulations, please find enclosed herewith the copies of newspaper advertisement published on May …
-
Audited Financial Results For Quarter And Year Ended March 31 2025
6 May - Audited FY25 financial results approved; new secretarial auditor appointed for 5 years, subject to shareholder approval.
-
Appointment Of Secretarial Auditor
6 May - Audited FY25 results approved with unmodified opinion; new secretarial auditor appointed for 5 years.
-
Board Meeting Outcome for Approval Of Audited Financial Results For Quarter And Year Ended March 31 2025
6 May - Audited FY25 results approved with profit; new secretarial auditor appointed for five years.
-
Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025.
1 May - Board meeting on May 6, 2025, to approve audited financial results for FY 2024-25.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1]
a) Manufacturing, distribution and dealing
of peroxygen chemicals
b) Making long term investments and corporate lending directly and/or through its wholly owned subsidiary viz., the Transferor Company.